Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:44:42.806Z.
Calculation as of: 2026-10-06T17:44:42.806Z.
Quote observation: 2026-10-06T17:40:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f896dd83f1f74da7f4e84885d6bb04cd833df246353afdbeec9bf8c0bdc7d1c4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$258.73M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.31M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$263.43M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.88M
EBITDA Yield
N/A
TTM Avg
10.04%
3Y Avg
10.04%
5Y Avg
9.67%
Market Cap
$256.82M
EBITDA Yield
0.21%
TTM Avg
12.97%
3Y Avg
7.82%
5Y Avg
5.93%
Market Cap
$264.03M
EBITDA Yield
N/A
TTM Avg
55.26%
3Y Avg
33.09%
5Y Avg
19.40%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. (XFOR) | $259.85M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $259.50M | N/A | 0.00% | 0.00% | 0.00% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $258.73M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $258.00M | N/A | 11.24% | 13.49% | 12.26% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $261.31M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.43M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.88M | N/A | 10.04% | 10.04% | 9.67% |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.82M | 0.21% | 12.97% | 7.82% | 5.93% |
| OraSure Technologies, Inc. (OSUR)vs › | $264.03M | N/A | 55.26% | 33.09% | 19.40% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $266.62M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
